Cero Therapeutics Amends Note and Secures $671,600 Advance
Cero Therapeutics entered a second amended and restated convertible note for up to $2.09 million, securing an initial $671,600 advance. This financing agreement represents a liquidity boost for the clinical-stage biopharmaceutical company.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day